Foresee Pharmaceuticals' April revenue up by 17%, continues to expect strong performance in new drug sales in the United States

Foresee Pharmaceuticals announced a consolidated revenue of approximately 49.87 million yuan in April, a monthly growth of 17%, a significant increase of 39,165% compared to the same period last year. Foresee's cumulative consolidated revenue for the first four months is approximately 150 million yuan, a significant increase of 439% compared to the same period last year. The company stated that the consolidated revenue for April includes sales income of 41.19 million yuan for supplying the CAMCEVI six-month dosage form to U.S. distributors and a sales profit of 8.68 million yuan for the CAMCEVI six-month dosage form in the U.S. market.